JP2005501110A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501110A5
JP2005501110A5 JP2003522564A JP2003522564A JP2005501110A5 JP 2005501110 A5 JP2005501110 A5 JP 2005501110A5 JP 2003522564 A JP2003522564 A JP 2003522564A JP 2003522564 A JP2003522564 A JP 2003522564A JP 2005501110 A5 JP2005501110 A5 JP 2005501110A5
Authority
JP
Japan
Prior art keywords
hdl
use according
administered
ischemia
reperfusion injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003522564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501110A (ja
JP4284177B2 (ja
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed filed Critical
Priority claimed from PCT/EP2002/009294 external-priority patent/WO2003018047A2/en
Publication of JP2005501110A publication Critical patent/JP2005501110A/ja
Publication of JP2005501110A5 publication Critical patent/JP2005501110A5/ja
Application granted granted Critical
Publication of JP4284177B2 publication Critical patent/JP4284177B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003522564A 2001-08-20 2002-08-20 脳卒中および他の虚血性症状の治療用hdl Expired - Fee Related JP4284177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Publications (3)

Publication Number Publication Date
JP2005501110A JP2005501110A (ja) 2005-01-13
JP2005501110A5 true JP2005501110A5 (https=) 2005-12-22
JP4284177B2 JP4284177B2 (ja) 2009-06-24

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003522564A Expired - Fee Related JP4284177B2 (ja) 2001-08-20 2002-08-20 脳卒中および他の虚血性症状の治療用hdl

Country Status (10)

Country Link
US (2) US20040266660A1 (https=)
EP (1) EP1425031B8 (https=)
JP (1) JP4284177B2 (https=)
AT (1) ATE396736T1 (https=)
AU (1) AU2002340825B2 (https=)
CA (1) CA2457840C (https=)
DE (1) DE60226881D1 (https=)
ES (1) ES2304452T3 (https=)
WO (1) WO2003018047A2 (https=)
ZA (1) ZA200401360B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
WO2010151096A1 (en) 2009-06-25 2010-12-29 Tetra, Sia Therapeutic combinations of nicotinic acid and meldonium
JP2012532919A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療因子を含むhdlおよび治療における使用
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US20120189612A1 (en) * 2011-01-25 2012-07-26 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
AU2012236889A1 (en) * 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
EP3668600B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
US12599677B2 (en) 2020-10-05 2026-04-14 Northwestern University Targeted PH sensitive liposomes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2026008645A1 (en) 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク インコーポレイテッド Hdlコレステロール値を上昇させる組成物および方法
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Similar Documents

Publication Publication Date Title
JP2005501110A5 (https=)
CA2457840A1 (en) Hdl for the treatment of stroke and other ischemic conditions
ES2200171T3 (es) Combinaciones de vasopresina y agentes adrenergeticos para el tratamiento del paro cardiaco.
JP2007514750A5 (https=)
Albin et al. Large-volume liposuction in 181 patients
CN101287457A (zh) Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
JP2022530615A5 (https=)
JP2002528502A5 (https=)
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
AU2003282464B2 (en) Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
JP2002523437A5 (https=)
JP2002530353A5 (https=)
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
Cassuto et al. Potent inhibition of burn pain without use of opiates
EP1703913B1 (en) Use of ribose in recovery from anaesthesia
Komatsu et al. Effect of hemoglobin vesicle, a cellular-type artificial oxygen carrier, on middle cerebral artery occlusion-and arachidonic acid-induced stroke models in rats
CN103664936A (zh) 一类治疗创伤性脑损伤疾病的化合物及其用途
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
JP2008505087A5 (https=)
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
RU2267335C1 (ru) Способ комбинированной анальгезии у пожилых пациентов после операций на тазобедренном суставе и бедре
JP4965791B2 (ja) 敗血症性ショックの治療方法
JPH027293B2 (https=)